Nutex Health receives Nasdaq delisting notice for bid price non-compliance; appeals, hearing July 9

Nutex Health Inc.

Nasdaq notified Nutex that it failed to regain the $1.00 minimum bid price by May 20, 2024.
Company requested an appeal hearing before Nasdaq Hearings Panel, staying delisting; hearing set for July 9, 2024.
Board approved a reverse stock split (1:2 to 1:16) subject to shareholder vote at June 17, 2024 Annual Meeting.
If appeal fails and compliance not regained, common stock could be suspended from Nasdaq trading.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.